domenica, 9 agosto 2026

Notizie AIOM – anno XV n. 640

A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer

Salvage radiotherapy (SRT) is a standard of care for men who recur postprostatectomy, and recent randomized trials have assessed the benefit and toxicity of adding hormone therapy (HT) to SRT with differing results. To perform a systematic review of randomized phase III ...
Leggi tutto

Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths globally. However, the identification of oncogenic driver alterations involved in the initiation and maintenance of NSCLC, such as epidermal growth factor receptor mutations and anaplastic ...
Leggi tutto

Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

August 24, 2017 - As reported in the Journal of Oncology Practice by Chang et al, for the first time for any type of malignancy, the American Urological Association (AUA), ASCO, American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO) have ...
Leggi tutto

FDA Approval Sought for Frontline Cabozantinib in RCC

August 16, 2017 - A supplemental new drug application (sNDA) has been submitted to the FDA for cabozantinib for previously untreated patients with advanced renal cell carcinoma (RCC), according to Exelixis, the developer of the multikinase inhibitor. The sNDA is based on ...
Leggi tutto

FDA Approves Ibrutinib for GVHD

August 2, 2017 - The FDA has approved ibrutinib for the treatment of adult patients with chronic graft versus host disease (cGVHD) following the failure of 1 or more lines of systemic therapy. The BTK inhibitor is now the first FDA-approved therapy for the treatment of cGVHD. ...
Leggi tutto

FDA Approves Inotuzumab Ozogamicin for ALL

August 17, 2017 - The FDA has approved inotuzumab ozogamicin for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), based on findings from the phase III INO-VATE trial. The approval comes with a boxed warning for hepatotoxicity ...
Leggi tutto

Scuola civica di alta formazione. Diritti e partecipazione in sanità

Parte a settembre, con quattro percorsi brevi dedicati a temi e questioni centrali per la sanità, la ‘Scuola civica di alta formazione. Diritti e partecipazione in sanità’, iniziativa del Tribunale dei diritti del malato di Cittadinanzattiva per ...
Leggi tutto

Premio ai 4 migliori progetti di ricerca in artrite psoriasica, psoriasi, mieloma multiplo e carcinoma del pancreas

Il concorso è destinato a medici o biologi di età inferiore o uguale a 40 anni Realizzato in collaborazione con le Società Scientifiche AIOM, SIDeMaST, SIE e SIR Scadenza presentazione progetti: 15 settembre 2017

ASCO Updates Treatment Guidelines for Advanced NSCLC

August 15, 2017 - ASCO has updated its guidelines for first- and second-line treatment of patients with stage IV non–small cell lung cancer (NSCLC). The organization has created new recommendations regarding the use of immunotherapy, and updated advice on targeted ...
Leggi tutto

ASCO Guideline on Stage IV NSCLC Therapy Updated

August 16, 2017 - An update of the ASCO clinical practice guideline on the systemic treatment of patients with stage IV non–small cell lung cancer (NSCLC) clarifies the role of immunotherapy in this setting. The update, published by Hanna et al in the Journal of Clinical ...
Leggi tutto